Content versus Label Claims in Cannabidiol (CBD)-Containing Products Obtained from Commercial Outlets in the State of Mississippi
Content versus Label Claims in Cannabidiol (CBD)-Containing Products Obtained from Commercial Outlets in the State of Mississippi
复制标题
DOI：
10.1080/19390211.2020.1766634
复制
发表时间：
2020-05-19
影响因子：
2.5
通讯作者：
ElSohly, Mahmoud
中科院分区：
文献类型：
--
作者：
Gurley, Bill J.;Murphy, Timothy P.;ElSohly, Mahmoud
含有大麻二酚（CBD）的产品现在在美国各地都可以买到，但它们的质量经常受到质疑。通过气相色谱/火焰电离检测（GC/FID）测定了在密西西比州获得的25种市售大麻油产品的CBD和Delta(9)-四氢大麻酚（THC）含量。这些产品还使用全扫描气相色谱/质谱（GC/MS）分析合成大麻素的存在。分析结果与CBD含量的标签声明进行了比较。产品标签上声称CBD的含量从无到每份500毫克不等；然而，在实际CBD含量和声称的数量之间观察到明显的差异。在这25种产品中，只有3种产品与标签上声称的相差在+/- 20%以内。15个远低于声明的CBD含量；其中两项超过索赔金额的50%；5人没有提出要求。此外，三种产品的四氢大麻酚含量超过0.3%的法定限量。此外，四种主要用于电子烟的产品掺入了合成大麻素。从这个小而多样的大麻衍生商品抽样来看，似乎大多数产品标签声明并不能准确反映实际的CBD含量，在这方面是欺诈的。此外，超过法定四氢大麻酚含量的产品可能会危及消费者的就业状况（即未通过“药物测试”），而掺入合成大麻素的产品可能会对消费者的健康造成严重的不利影响。这些发现有力地证明了进一步发展当前含cbd产品的良好生产规范及其严格执行的必要性。
Products containing cannabidiol (CBD) are now available throughout the United States, but their quality is oftentimes questionable. The CBD and Delta(9)-tetrahydrocannabinol (THC) content of 25 commercially available hemp oil products, obtained throughout the state of Mississippi, was determined via gas chromatography/flame ionization detection (GC/FID). These products were also analyzed for the presence of synthetic cannabinoids using full scan gas chromatography/mass spectrometry (GC/MS). Analytical findings were compared to label claims for CBD content. Product label claims for CBD ranged from no claim to 500 mg per serving; however, marked variability was observed between actual CBD content and claimed quantities. Of the 25 products, only three were within +/- 20% of label claim. Fifteen were well below the stated claim for CBD; two exceed claims in excess of 50%; and 5 made no claims. In addition, THC content for three products exceeded the 0.3% legal limit. Furthermore, four products-primarily marketed for vaping-were adulterated with synthetic cannabinoids. From this small, but diverse, sampling of hemp-derived merchandise, it appears that most product label claims do not accurately reflect actual CBD content and are fraudulent in that regard. Moreover, products that exceed legal THC levels may jeopardize a consumer's employment status (i.e. failed "drug test"), while those adulterated with synthetic cannabinoids may subject them to serious adverse health effects. These findings argue strongly for further development of current good manufacturing practices for CBD-containing products and their stringent enforcement.